$0.77
0.0869[12.72%]
At close: Apr 29
$0.77
0[0.00%]
After Hours: 7:05PM EDT
Lucid Diagnostics
(NASDAQ:LUCD)Lucid Diagnostics Stock (NASDAQ:LUCD), Analyst Ratings, Price Targets, Predictions
Lucid Diagnostics Inc has a consensus price target of $6.83, established from looking at the 24 latest analyst ratings. The last 3 analyst ratings were released from Needham, Cantor Fitzgerald, and Needham on April 12, 2024, March 27, 2024, and March 27, 2024. With an average price target of $2.67 between Needham, Cantor Fitzgerald, and Needham, there's an implied 246.32% upside for Lucid Diagnostics Inc from these 3 analyst ratings.
Analyst Firms Making Recommendations1
Needham
Cantor Fitzgerald
Cantor Fitzgerald
BTIG
Canaccord Genuity
1calculated from analyst ratings published within the last 3 years
Analyst Ratings for Lucid Diagnostics
date | ticker | Buy Now | Company | Current price | Upside/Downside | Analyst Firm | Analyst & % Accurate | Price Target Change | Rating Change | Previous / Current Rating | Get Alert |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 04/12/2024 | LUCD | Buy Now | Lucid Diagnostics | $0.77 | 224.68% | Needham | Mike Matson | → $2.5 | Reiterates | Buy → Buy | Get Alert |
| 03/27/2024 | LUCD | Buy Now | Lucid Diagnostics | $0.77 | 289.61% | Cantor Fitzgerald | Ross Osborn | $3.8 → $3 | Maintains | Overweight | Get Alert |
| 03/27/2024 | LUCD | Buy Now | Lucid Diagnostics | $0.77 | 224.68% | Needham | Mike Matson | → $2.5 | Reiterates | Buy → Buy | Get Alert |
| 11/14/2023 | LUCD | Buy Now | Lucid Diagnostics | $0.77 | 224.68% | Needham | Mike Matson | $2.8 → $2.5 | Maintains | Buy | Get Alert |
| 09/26/2023 | LUCD | Buy Now | Lucid Diagnostics | $0.77 | 419.48% | Cantor Fitzgerald | Ross Osborn | → $4 | Reiterates | Overweight → Overweight | Get Alert |
| 08/22/2023 | LUCD | Buy Now | Lucid Diagnostics | $0.77 | 419.48% | Cantor Fitzgerald | Charles Duncan | → $4 | Reiterates | Overweight → Overweight | Get Alert |
| 08/16/2023 | LUCD | Buy Now | Lucid Diagnostics | $0.77 | 419.48% | Cantor Fitzgerald | Charles Duncan | → $4 | Reiterates | Overweight → Overweight | Get Alert |
| 08/16/2023 | LUCD | Buy Now | Lucid Diagnostics | $0.77 | 263.64% | Needham | Mike Matson | → $2.8 | Reiterates | Buy → Buy | Get Alert |
| 05/17/2023 | LUCD | Buy Now | Lucid Diagnostics | $0.77 | 419.48% | Cantor Fitzgerald | Charles Duncan | $4.5 → $4 | Maintains | Overweight | Get Alert |
| 05/17/2023 | LUCD | Buy Now | Lucid Diagnostics | $0.77 | 263.64% | Needham | Mike Matson | $2.6 → $2.8 | Maintains | Buy | Get Alert |
| 04/21/2023 | LUCD | Buy Now | Lucid Diagnostics | $0.77 | 237.66% | Needham | Mike Matson | → $2.6 | Reiterates | → Buy | Get Alert |
| 03/14/2023 | LUCD | Buy Now | Lucid Diagnostics | $0.77 | 237.66% | Needham | Mike Matson | $3.1 → $2.6 | Maintains | Buy | Get Alert |
| 11/18/2022 | LUCD | Buy Now | Lucid Diagnostics | $0.77 | 354.55% | BTIG | Mark Massaro | $5 → $3.5 | Maintains | Buy | Get Alert |
| 11/15/2022 | LUCD | Buy Now | Lucid Diagnostics | $0.77 | 302.6% | Needham | Mike Matson | $4.25 → $3.1 | Maintains | Buy | Get Alert |
| 08/16/2022 | LUCD | Buy Now | Lucid Diagnostics | $0.77 | 451.95% | Needham | Mike Matson | $5 → $4.25 | Maintains | Buy | Get Alert |
| 05/12/2022 | LUCD | Buy Now | Lucid Diagnostics | $0.77 | 549.35% | Needham | Mike Matson | $7 → $5 | Maintains | Buy | Get Alert |
| 03/29/2022 | LUCD | Buy Now | Lucid Diagnostics | $0.77 | 1458.44% | Canaccord Genuity | Kyle Mikson | $18 → $12 | Maintains | Buy | Get Alert |
| 03/29/2022 | LUCD | Buy Now | Lucid Diagnostics | $0.77 | 809.09% | Needham | Mike Matson | $13 → $7 | Maintains | Buy | Get Alert |
| 12/27/2021 | LUCD | Buy Now | Lucid Diagnostics | $0.77 | 1977.92% | Ascendiant Capital | Edward Woo | → $16 | Initiates | → Buy | Get Alert |
FAQ
What is the target price for Lucid Diagnostics (LUCD)?
The latest price target for Lucid Diagnostics (NASDAQ: LUCD) was reported by Needham on April 12, 2024. The analyst firm set a price target for $2.50 expecting LUCD to rise to within 12 months (a possible 224.68% upside). 10 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Lucid Diagnostics (LUCD)?
The latest analyst rating for Lucid Diagnostics (NASDAQ: LUCD) was provided by Needham, and Lucid Diagnostics reiterated their buy rating.
When was the last upgrade for Lucid Diagnostics (LUCD)?
There is no last upgrade for Lucid Diagnostics.
When was the last downgrade for Lucid Diagnostics (LUCD)?
There is no last downgrade for Lucid Diagnostics.
When is the next analyst rating going to be posted or updated for Lucid Diagnostics (LUCD)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Lucid Diagnostics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Lucid Diagnostics was filed on April 12, 2024 so you should expect the next rating to be made available sometime around April 12, 2025.
Is the Analyst Rating Lucid Diagnostics (LUCD) correct?
While ratings are subjective and will change, the latest Lucid Diagnostics (LUCD) rating was a reiterated with a price target of $0.00 to $2.50. The current price Lucid Diagnostics (LUCD) is trading at is $0.77, which is within the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.